Please assess the completion status of the following clinical trial:

Trial Title: University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be able to communicate meaningfully with the investigators and be legally competent to provide written informed consent.~2. Age range between 18 to 70 years (inclusive).~3. Female patients must be non-lactating and must either be at least one year post-menopausal, or be using adequate mechanical contraceptive precautions (i.e. intrauterine device, diaphragm with spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy). Female patients who have undergone a hysterectomy are eligible for participation in the study. Female patients (except for those patients who have undergone a hysterectomy or a bilateral oophorectomy) are eligible only if they have a negative pregnancy test throughout the study period. Patients on oral contraceptives or an hormonal implant will be excluded (patches are acceptable as they deliver much lower estrogen systemically).~4. Participants must have the following laboratory values:~   * Hemoglobin ≥ 12 gm/dl in males, or ≥ 11 gm/dl in females,~  * WBC count ≥ 3,000/mm3~  * Neutrophil count ≥ 1,500/mm3~  * Platelets ≥ 100,000/mm3~  * Albumin ≥3.0 g/dl~  * Serum creatinine ≤ 1.8 mg/dl~  * Creatinine phosphokinase ≤ 2 times upper limit of normal~  * AST and ALT ≤ 3.0 times upper limit of normal~  * Alkaline phosphatase ≤ 2.5 times upper limit of normal~5. A diagnosis of NASH by liver biopsy performed within the past 6 months,~Exclusion Criteria:~1. Any cause of chronic liver disease other than NASH (such as -but not restricted to- alcohol or drug abuse, medication, chronic hepatitis B or C, autoimmune, hemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency).~2. Any clinical evidence or history of ascitis, bleeding varices, or spontaneous encephalopathy.~3. Current history of alcohol abuse (alcohol consumption greater than 20 grams of ethanol per day).~4. Prior surgical procedures to include gastroplasty, jejuno-ileal or jejunocolic bypass.~5. Prior exposure to organic solvents such as carbon tetrachloride.~6. Total parenteral nutrition (TPN) within the past 6 months.~7. Subjects with type 1 diabetes mellitus.~8. Patients on chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on a stable dose of such agents for 4 weeks before entry into the study. Patients on estrogens or other hormonal replacement therapy, tamoxifen, raloxifene, oral glucocorticoids or chloroquine will be excluded.~9. Patients with a history of clinically significant heart disease (New York Heart Classification greater than grade II), peripheral vascular disease (history of claudication), or diagnosed pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation).~10. Patients with severe osteoporosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Pioglitazone (Type: ACTIVE_COMPARATOR): After all patients receive dietary counseling at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
- Placebo (Type: PLACEBO_COMPARATOR): After dietary counseling to all patients at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).

Based on this trial design, predict the completion outcome and termination type (if applicable).